Biosimilar Antibodies
Biosimilar Antibodies
Why choose Biosimilar Antibodies?
- Cost-effective and reliable alternatives to reference biologics.
- Validated for diverse applications, including ELISAs, flow cytometry, and Western blotting.
- Suitable for biophysical characterization (SPR) and immunohistochemistry (IHC).
- Proven functionality in blocking, neutralization, co-stimulation, and depletion assays.
Our Biosimilar Range
VivoGenie BiosimilarsLow Endotoxin for in vivo studies
Reference BiosimilarsIn vitro investigations & comparison studies
Conjugated BiosimilarsLabeled with different dyes or enzymes
Testimonials & Partners
"I ordered from AssayGenie for the first time and would like to share my satisfied impression. The article (Bevacizumab; IVMB0232) was used as a positive control and works excellently in Biacore SPR measurements and VEGF bioassay"
- G. Carsten, Fraunhofer (2024)
cGMP & ISO Certification
Quality is at the core of everything we do.
Manufactured in state-of-the-art facilities, our products meet the highest standards, including current Good Manufacturing Practicies) cGMP, ISO 9001:2015, and ISO 13485:2016 certifications. These ensure consistent quality, customer-focused innovation, and reliable performance in every batch.
Biosimilar Production
Biosimilar Antibody Product Data
VivoGenie Biosimilars
VivoGenie Biosimilars
With low endotoxin levels (≤1.0 EU/mg) and minimal aggregation (≥95% monomer verified by SEC), they are ideal for sensitive applications. Formulated in sterile PBS (pH 7.2) without preservatives, stabilizers, or carrier proteins.
Reference Biosimilars
Conjugated Biosimilars
Meet Some of the Genie Team!
Shane, Sales
Natalia, Tech Support
Chris, Sales
Beatriz, Logistics
Marina, Tech Support
Miren, Sales
José, Sales
David, Sales
FAQs & Citations
1. What are research-grade biosimilars?
Research-grade biosimilars are laboratory-produced proteins that are designed to mimic the structure and function of approved biologic drugs. They are used in preclinical studies, assay development, and other non-clinical applications.
2. How do research-grade biosimilars differ from therapeutic biosimilars?
Research-grade biosimilars are intended for laboratory and research purposes only. They are not subject to the same regulatory scrutiny as therapeutic biosimilars, which must undergo clinical trials and approval processes for patient use.
3. Are research-grade biosimilars the same as reference biologics?
No, research-grade biosimilars are designed to be similar in structure and function to reference biologics but are not identical. They are primarily used for assay development, drug screening, and in vitro/in vivo research.
4. Are research-grade biosimilars produced using the same expression systems as the original biologics?
They may be produced in similar systems (e.g., CHO cells, E. coli, yeast), but there can be differences in post-translational modifications, glycosylation patterns, or impurities.
5. How is the quality of research-grade biosimilars ensured?
Quality is assessed through purity analysis (SDS-PAGE, HPLC, Mass Spectrometry), bioactivity assays, and binding affinity tests (e.g., ELISA, SPR, BLI).
6. What are common applications of research-grade biosimilars?
- Preclinical drug screening
- Assay development and validation (e.g., ELISA, Western Blot, Flow Cytometry)
- Mechanism of action studies
- Comparative studies against reference biologics
7. Can research-grade biosimilars be used in animal studies?
Yes, they can be used in in vivo models to study pharmacokinetics, pharmacodynamics, and efficacy before moving to clinical-grade biosimilars.
1. Turley, Joanna L., et al. "Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8+ T cell-dependent anti-tumor immunity." Cell Reports Medicine 5.5 (2024).
2. Petropoulos, Michalis, et al. "Transcription–replication conflicts underlie sensitivity to PARP inhibitors." Nature 628.8007 (2024): 433-441.
3. Membrez, Mathieu, et al. "Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia." Nature metabolism 6.3 (2024): 433-447.
4. Bikorimana, Jean Pierre, et al. "Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth." Journal of Translational Medicine 22.1 (2024): 532.
5. Wang, Ziyin, et al. "Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice." Molecular Therapy-Nucleic Acids 34 (2023).
Biosimilar Resources - Blogs & Podcast Episodes
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the mechanism of action for Siltuximab?Siltuximab binds to IL-6, preventing it from interacting with its receptor and mitigating downstream pro-inflammatory signaling.What [...]
Related Products
Additional Resources
